Patent ID: 11892450
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC C  G

Claim 0:
1. A method of treating a subject having a plasma kallikrein (pKal)-mediated disorder, the method comprising:
(i) contacting a sample obtained from the subject containing plasma protease C1 inhibitor (C1-INH) with a capture reagent; wherein the capture reagent comprises:
a) an active form of Factor XII, or a C1-INH binding fragment thereof,
b) an active form of pKal, or a C1-INH binding fragment thereof, or
c) a combination of a) and b);

(ii) measuring a level of the C1-INH in the sample that binds to the capture reagent,
(iii)—identifying the subject as having a pKal-mediated disorder, wherein the level of the C1-INH obtained in step (i) being reduced relative to the level of the C1-INH in a healthy subject is indicative of occurrence of the pKal-mediated disorder; and
(iv) administering an effective amount of a therapeutic agent to the subject identified in step (iii);
wherein the therapeutic agent is a plasma kallikrein inhibitor, a bradykinin B2 receptor antagonist or a C1-INH replacement agent; and
wherein the pKal-mediated disorder is selected from the group consisting of rheumatoid arthritis, Crohn's disease, brain ischemia/reperfusion injury, cerebral edema, macular edema, arterial or venous thrombosis, thrombosis associated with ventricular assist devices or stents, heparin-induced thrombocytopenia with thrombosis, thromboembolic disease, intestinal bowel disease, and hereditary angioedema (HAE).